Department of Internal Medicine and Therapeutics, University of Pavia, and Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy.
J Biol Regul Homeost Agents. 2014 Apr-Jun;28(2):317-24.
The aim of this study was to evaluate the effects of a combination of red yeast rice, Silybum marianum and octasonol compared to placebo on lipid profile, endothelial, and inflammatory parameters in low risk dislipidemic patients. One hundred and thirty-four dislipidemic patients were randomised to take placebo or a patented nutraceutical association in tablet form (Zeta ColestRT), 1 tablet /day (immediately after the dinner), for three months in a double-blind, placebo-controlled trial. At baseline and after 3 months the following were evaluated: body weight, body mass index (BMI), fasting plasma glucose (FPG), lipid profile, soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble E-selectin (sE-selectin), metalloprotineases-2 and -9 (MMP-2 and MMP-9), high sensitivity C-reactive protein (Hs-CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha). The nutraceutical combination decreased total cholesterol and low density lipoprotein cholesterol compared to baseline (p = 0.042, and p = 0.041, respectively) and to placebo (p = 0.039, and p = 0.037, respectively). Triglycerides were reduced by the active treatment (p = 0.039), but not by placebo, even if, in group to group comparison, no differences were recorded (p = 0.061). All adipocytokines were reduced by the nutraceutical combination, in particular p = 0.044 for sICAM-1, p = 0.045 for sVCAM-1, p = 0.040 for sE-selectin, p = 0.035 for MMP-2, p = 0.039 for MMP-9, p = 0.038 for Hs-CRP, p = 0.036 for TNF-α, and p = 0.036 for IL-6 compared to baseline, and p = 0.042 for sICAM-1, p = 0.043 for sVCAM-1, p = 0.042 for sE-selectin, p = 0.031 for MMP-2, p = 0.038 for MMP-9, p =0.038 for Hs-CRP, and p = 0.043 for TNF-alpha, espectively, compared to placebo. We can conclude that a combination of red yeast rice, Silybum marianum and octasonol was effective in improving lipid profile, endothelial, and inflammatory parameters in low risk dislipidemic patients.
本研究旨在评估红曲米、水飞蓟素和八角素组合与安慰剂相比，对低危血脂异常患者的血脂谱、内皮和炎症参数的影响。134 名血脂异常患者被随机分配服用安慰剂或专利营养保健品（Zeta ColestRT），每天 1 片（晚饭后立即服用），进行为期 3 个月的双盲、安慰剂对照试验。在基线和 3 个月后评估以下参数：体重、体重指数（BMI）、空腹血糖（FPG）、血脂谱、可溶性细胞间黏附分子-1（sICAM-1）、可溶性血管细胞黏附分子-1（sVCAM-1）、可溶性 E-选择素（sE-selectin）、金属蛋白酶-2 和 -9（MMP-2 和 MMP-9）、高敏 C 反应蛋白（Hs-CRP）、白细胞介素-6（IL-6）和肿瘤坏死因子-α（TNF-α）。营养保健品组合可降低总胆固醇和低密度脂蛋白胆固醇，与基线相比（p=0.042 和 p=0.041）和安慰剂相比（p=0.039 和 p=0.037）。活性治疗可降低甘油三酯（p=0.039），但安慰剂组无此作用，尽管组间比较无差异（p=0.061）。营养保健品组合可降低所有脂肪细胞因子，特别是 sICAM-1 降低 0.044（p=0.044），sVCAM-1 降低 0.045（p=0.045），sE-selectin 降低 0.040（p=0.040），MMP-2 降低 0.035（p=0.035），MMP-9 降低 0.039（p=0.039），Hs-CRP 降低 0.038（p=0.038），TNF-α降低 0.036（p=0.036），与基线相比，sICAM-1 降低 0.042（p=0.042），sVCAM-1 降低 0.043（p=0.043），sE-selectin 降低 0.042（p=0.042），MMP-2 降低 0.031（p=0.031），MMP-9 降低 0.038（p=0.038），Hs-CRP 降低 0.038（p=0.038），TNF-α降低 0.043（p=0.043）。我们可以得出结论，红曲米、水飞蓟素和八角素的组合在改善低危血脂异常患者的血脂谱、内皮和炎症参数方面是有效的。
